Epidemiology and clinical outcome of pyogenic liver abscess: an analysis from the National Health Insurance Research Database of Taiwan, 2000–2011

Journal of Microbiology, Immunology and Infection

Volumn 49, Issue 5, 2016, Pages 646-653

  Chen, Yung Chun ^a   Lin, Ching Heng ^a   Chang, Shih Ni ^a   Shi, Zhi Yuan ^a,b  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Clinical outcome; National Health Insurance Research Database; Pyogenic liver abscess

Indexed keywords

CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL OUTCOME; DIABETES MELLITUS; FAMILY INCOME; FEMALE; GROUPS BY AGE; HUMAN; INCIDENCE; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; NATIONAL HEALTH INSURANCE; PYOGENIC LIVER ABSCESS; TAIWAN; ESCHERICHIA COLI INFECTIONS; KLEBSIELLA INFECTIONS; LIVER ABSCESS, PYOGENIC; MIDDLE AGED; MORTALITY; YOUNG ADULT;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CEFAZOLIN; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; LIVER ABSCESS, PYOGENIC; MALE; MIDDLE AGED; TAIWAN; YOUNG ADULT;

EID: 84992424443     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2014.08.028     Document Type: Article

References (25)

1. 1 Lau, Y.J., Hu, B.S., Wu, W.L., Lin, Y.H., Chang, H.Y., et al. Identification of a major cluster of Klebsiella pneumoniae isolates from patients with liver abscess in Taiwan. J Clin Microbiol 38 (2000), 412–414.
2. 2 Frey, C.F., Zhu, Y., Suzuki, M., Isaji, S., Liver abscesses. Surg Clin North Am 69 (1989), 259–271.
3. 3 Seeto, R.K., Rockey, D.C., Pyogenic liver abscess. Changes in etiology, management, and outcome. Medicine (Baltimore) 75 (1996), 99–113.
4. 4 Chang, F.Y., Chou, M.Y., Comparison of pyogenic liver abscesses caused by Klebsiella pneumoniae and non-K. pneumoniae pathogens. J Formos Med Assoc 94 (1995), 232–237.
5. 5 Yang, C.C., Yen, C.H., Ho, M.W., Wang, J.H., Comparison of pyogenic liver abscess caused by non-Klebsiella pneumoniae and Klebsiella pneumoniae. J Microbiol Immunol Infect 37 (2004), 176–184.
6. 6 Liu, Y.C., Cheng, D.L., Lin, C.L., Klebsiella pneumoniae liver abscess associated with septic endophthalmitis. Arch Intern Med 146 (1986), 1913–1916.
7. 7 Cheng, D.L., Liu, Y.C., Yen, M.Y., Liu, C.Y., Wang, R.S., Septic metastatic lesions of pyogenic liver abscess. Their association with Klebsiella pneumoniae bacteremia in diabetic patients. Arch Intern Med 151 (1991), 1557–1559.
8. 8 Wang, J.H., Liu, Y.C., Lee, S.S., Yen, M.Y., Chen, Y.S., Wang, J.H., et al. Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis 26 (1998), 1434–1438.
9. 9 Lee, K.T., Wong, S.R., Sheen, P.C., Pyogenic liver abscess: an audit of 10 years' experience and analysis of risk factors. Dig Surg 18 (2001), 459–465 discussion 65–6.
10. 10 Lee, S.S., Chen, Y.S., Tsai, H.C., Wann, S.R., Lin, H.H., Huang, C.K., et al. Predictors of septic metastatic infection and mortality among patients with Klebsiella pneumoniae liver abscess. Clin Infect Dis 47 (2008), 642–650.
11. 11 Tsai, F.C., Huang, Y.T., Chang, L.Y., Wang, J.T., Pyogenic liver abscess as endemic disease, Taiwan. Emerg Infect Dis 14 (2008), 1592–1600.
12. 12 Cheng, H.P., Siu, L.K., Chang, F.Y., Extended-spectrum cephalosporin compared to cefazolin for treatment of Klebsiella pneumoniae-caused liver abscess. Antimicrol Agents Chemother 47 (2003), 2088–2092.
13. 13 Kaplan, G.G., Gregson, D.B., Laupland, K.B., Population-based study of the epidemiology of and the risk factors for pyogenic liver abscess. Clin Gastroenterol Hepatol 2 (2004), 1032–1038.
14. 14 Jepsen, P., Vilstrup, H., Schonheyder, H.C., Sorensen, H.T., A nationwide study of the incidence and 30-day mortality rate of pyogenic liver abscess in Denmark, 1977–2002. Aliment Pharmacol Ther 21 (2005), 1185–1188.
15. 15 Okano, H., Shiraki, K., Inoue, H., Kawakita, T., Yamamoto, N., Deguchi, M., et al. Clinicopathological analysis of liver abscess in Japan. Int J Mol Med 10 (2002), 627–630.
16. 16 Chung, D.R., Lee, S.S., Lee, H.R., Kim, H.B., Choi, H.J., Eom, J.S., et al. Emerging invasive liver abscess caused by K1 serotype Klebsiella pneumoniae in Korea. J Infect 54 (2007), 578–583.
17. 17 Lederman, E.R., Crum, N.F., Pyogenic liver abscess with a focus on Klebsiella pneumoniae as a primary pathogen: an emerging disease with unique clinical characteristics. Am J Gastroenterol 100 (2005), 322–331.
18. 18 Nadasy, K.A., Domiati-Saad, R., Tribble, M.A., Invasive Klebsiella pneumoniae syndrome in North America. Clin Infect Dis 45 (2007), e25–e28.
19. 19 Rahimian, J., Wilson, T., Oram, V., Holzman, R.S., Pyogenic liver abscess: recent trends in etiology and mortality. Clin Infect Dis 39 (2004), 1654–1659.
20. 20 Lai, H.C., Lin, C.C., Cheng, K.S., et al. Increased incidence of gastrointestinal cancers among patients with pyogenic liver abscess: a population-based cohort study. Gastroenterology, 146, 2014 129–37 e1.
21. 21 Kao, W.Y., Hwang, C.Y., Chang, Y.T., Kao, J.T., Chou, J.W., Peng, C.Y., et al. Cancer risk in patients with pyogenic liver abscess: a nationwide cohort study. Aliment Pharmacol Ther 36 (2012), 467–476.
22. 22 Fang, C.T., Lai, S.Y., Yi, W.C., Hsueh, P.R., Liu, K.L., Chang, S.C., Klebsiella pneumoniae genotype K1: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. Clin Infect Dis 45 (2007), 284–293.
23. 23 Wolff, M., Chavanet, P., Kazmierczak, A., Pechinot, A., Dematons, C., Portier, H., et al. Diffusion of cefpirome into the cerebrospinal fluid of patients with purulent meningitis. J Antimicrob Chemother 29:Suppl. A (1992), 59–62.
24. 24 Chandrasekar, P.H., Rolston, K.V., Smith, B.R., LeFrock, J.L., Diffusion of ceftriaxone into the cerebrospinal fluid of adults. J Antimicrob Chemother 14 (1984), 427–430.
25. 25 Fong, I.W., Tomkins, K.B., Penetration of ceftazidime into the cerebrospinal fluid of patients with and without evidence of meningeal inflammation. Antimicrob Agents Chemother 26 (1984), 115–116.